Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

NEW YORK, NY, USA I June 26, 2025 I Pfizer Inc. (NYSE: PFE)today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating ...

Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with ...

Preventive treatment with Pfizer's Hympavzi can reduce bleeding rates in hemophilia A or B patients with inhibitors, new ...

Pfizer Inc. (NYSE: PFE)today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for ...

Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

This release contains forward-looking information about HYMPAVZI™ (marstacimab), an anti-tissue factor pathway inhibitor, including its potential benefits and plans to discuss the Phase 3 BASIS ...

Marstacimab is a tissue factor pathway inhibitor antagonist approved under the brand name Hympavzi.

Marstacimab is a human monoclonal antibody that targets tissue factor pathway inhibitor. This inhibition enables an alternative blood clotting pathway that does not involve factor VIII or factor IX.

Concizumab for hemophilia: Novo Nordisk’s anti-tissue factor pathway inhibitor therapy is under review for prophylactic use in hemophilia A or B with inhibitors.